The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
|First Received Date||February 17, 2014|
|Last Changed Date||October 14, 2015|
|Start Date||September 2009|
|Anticipated Primary Completion Date||January 2017|
|Primary Outcome Measures||
Overall survival (OS) [Time Frame: 5 years]
|Secondary Outcome Measures||
Progression-free survival (PFS) [Time Frame: 5 years]
|Study Type||Observational [Patient Registry]|
|Study Arms / Comparison Groups||0 / 1|
The handling of patients with PSM involves multimodal and multidisciplinary treatment strategies such as CRS, the removal of all macroscopically detectable tumor, and HIPEC, instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease. The treatment is challenging and complex and associated with significant morbidity. Only patients with limited disease will benefit from the treatment, and better methods for patient selection are needed. The project group has a unique opportunity to address key questions because of acquired experience, an exceptional biobank and institutional database and novel animal models established at the Norwegian Radium Hospital.
|Ages||18 Years - N/A|
|Accepts Healthy Volunteers||No|
Kjersti Flatmark, MD PhD
Phone: +47 22 78 18 73
- age > 18 years
- confirmed diagnosis of peritoneal surface malignancy
- candidate for CRS-HIPEC
- written informed consent
Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
|Sponsor||Oslo University Hospital|
|Verification Date||October 2015|